Egrifta Sv Kit
Product Images NDC 62064-241

Product Visual Gallery

This gallery contains 27 technical images submitted to the FDA as part of the official labeling for Egrifta Sv (NDC 62064-241). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Theratechnologies Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Egr00 0001 01)

Chemical structure diagram of tesamorelin, the active ingredient in EGRIFTA SV. The diagram shows the sequence of amino acids in the peptide chain along with chemical groups characteristic of tesamorelin.*

FDA Label Image

Figure 1 (Egr00 0001 02)

A two-panel cumulative distribution plot depicting belly appearance distress change in Study 1 and Study 2. The x-axis shows belly appearance distress change from -100 (worse) to 100 (better), and the y-axis shows cumulative patients percentage from 0% to 100%. Treatment groups, placebo and tesamorelin, are distinguished by black and gray lines respectively, with a horizontal line marking the 50% cumulative patients level.*

FDA Label Image

Figure 2 (Egr00 0001 03)

Two line graphs titled Study 1 and Study 2 showing percent changes from baseline in VAT over time (Baseline, Weeks 13, 26, 39, 52). Each graph includes three lines representing groups T-T, T-P, and P-T with respective sample sizes listed. The y-axis ranges from -25% to 10%. The x-axis shows time points. The graphs depict how VAT changes vary across the groups and weeks in each study.*

FDA Label Image

Figure A (Egr00 0001 04)

An instructional illustration showing the contents of the EGRIFTA SV injection kit by Theratechnologies Inc. It includes a vial labeled EGRIFTA SV 2mg, sterile water vial for injection, two 1mL syringes with plungers, one-inch 20-gauge needles for mixing with protective caps, and a half-inch 30-gauge needle with a pink needle shield for injection, also with protective caps.*

FDA Label Image

Figure B (Egr00 0001 05)

An instructional diagram depicting hands preparing a syringe, likely for subcutaneous injection. The image shows two hands holding a syringe with arrows indicating the motion to mix or prepare the medication. This illustration is consistent with usage instructions for EGRIFTA SV (tesamorelin) kit for subcutaneous administration.*

FDA Label Image

Figure C (Egr00 0001 06)

An instructional line drawing showing a hand holding a syringe above a vial with another hand stabilizing the vial, indicating preparation for injection.*

FDA Label Image

Figure D (Egr00 0001 07)

An instructional illustration showing a hand injecting a subcutaneous dose into the forearm using a syringe. The diagram highlights the syringe scale indicating 0.5 mL volume for the injection, relevant for EGRIFTA SV (tesamorelin) kit subcutaneous administration.*

FDA Label Image

Figure E (Egr00 0001 08)

An instructional line drawing showing a person's hand holding a vial while a syringe is being inserted into its rubber stopper, with the other arm positioned nearby. The image likely demonstrates how to prepare a subcutaneous injection, consistent with the use of the EGRIFTA SV kit.*

FDA Label Image

Figure F (Egr00 0001 09)

An instructional illustration showing a hand drawing liquid from a vial into a syringe. The vial is held steady by the other hand, with an arrow indicating the upward motion of pulling the syringe plunger to withdraw the liquid. This image is related to the preparation of a subcutaneous injection.*

FDA Label Image

Figure G (Egr00 0001 10)

Illustration showing hands holding and rolling a small vial or bottle, likely demonstrating the proper technique for preparing or mixing a subcutaneous injection, such as EGRIFTA SV (tesamorelin).*

FDA Label Image

Figure I (Egr00 0001 12)

An instructional illustration showing hand technique for drawing medication from a vial into a syringe. One hand holds the vial steady on a flat surface while the other hand inserts the syringe needle into the vial with a downward motion indicated by an arrow.*

FDA Label Image

Figure J (Egr00 0001 13)

An instructional illustration showing hands drawing liquid from a vial into a syringe. A circular inset highlights the stopper of the vial being pierced by the syringe needle. This image likely demonstrates the preparation step for subcutaneous injection.*

FDA Label Image

Figure K (Egr00 0001 14)

An instructional diagram showing two hands preparing a syringe for injection. One hand holds the syringe with the plunger being pulled up, while the other hand steadies a vial. This illustration is consistent with preparation steps for subcutaneous injection, relevant to EGRIFTA SV (tesamorelin) kit.*

FDA Label Image

Figure L (Egr00 0001 15)

An instructional illustration showing a hand holding a syringe, with an arrow indicating the syringe barrel being pulled or pushed. This diagram likely demonstrates the proper way to handle or prepare the syringe for subcutaneous injection.*

FDA Label Image

Figure M (Egr00 0001 16)

An instructional black-and-white line drawing depicting two hands holding a syringe. Arrows indicate the action of pulling or separating parts of the syringe, demonstrating a preparatory step in using the EGRIFTA SV (tesamorelin) subcutaneous injection kit.*

FDA Label Image

Figure N (Egr00 0001 17)

Illustration showing a person holding a syringe and vial, demonstrating the process of drawing medication from the vial into the syringe. The drawing focuses on hand positioning to guide correct technique, likely related to subcutaneous injection preparation.*

FDA Label Image

Figure O (Egr00 0001 18)

An instructional illustration showing hands holding a syringe and vial. The image depicts the process of mixing or drawing medication from the vial into the syringe, likely part of preparing a subcutaneous injection dose for use with the EGRIFTA SV (tesamorelin) kit.*

FDA Label Image

Figure P (Egr00 0001 19)

An instructional illustration showing a person’s abdomen with a hand placed near a circular marked area labeled '2 in.' This diagram likely demonstrates the recommended 2-inch radius injection site for a subcutaneous administration, guiding where the EGRIFTA SV kit injections should be given.*

FDA Label Image

Figure Q (Egr00 0001 20)

Black and white instructional illustration showing two hands preparing a syringe, with one hand holding a vial and the other pulling the syringe plunger upward. The image visually guides the preparation of an injectable medication, likely for subcutaneous administration.*

FDA Label Image

Figure R (Egr00 0001 21)

An instructional illustration showing a hand holding a syringe with liquid, indicating how to measure a dose of 0.35 mL. It includes a zoomed-in view on the syringe scale highlighting the 0.3 to 0.4 mL range for accurate dosing.*

FDA Label Image

Figure S (Egr00 0001 22)

An instructional line drawing showing a person with a rounded abdomen, holding the side of their belly with one hand. The illustration likely demonstrates the subcutaneous injection site area relevant to EGRIFTA SV (tesamorelin) usage.*

FDA Label Image

Figure T (Egr00 0001 23)

Instructional line drawing showing a person injecting a subcutaneous dose into the abdomen at a 90-degree angle, illustrating how to administer an injection for a kit dosage form.*

FDA Label Image

Figure U (Egr00 0001 24)

Instructional illustration showing a person performing a subcutaneous injection into the abdomen. The image demonstrates proper needle insertion angle and hand positioning for administering medication via subcutaneous route.*

FDA Label Image

Figure V (Egr00 0001 25)

An instructional illustration showing hands preparing to administer a subcutaneous injection using a pen device. The image highlights the step of clicking or attaching the needle or device at the injection site, emphasizing proper handling technique.*

FDA Label Image

Principal Display Panel (Medication Box)

EGRIFTA SV 2 mg/vial medication box label for tesamorelin sterile lyophilized powder, supplied as a kit for subcutaneous injection. The label states a package size of 30 vials and highlights storage instructions to protect from light and keep at room temperature up to 77°F (25°C). Labeler is Theratechnologies Inc., with NDC 62064-241-30.*

FDA Label Image

Principal Display Panel (Injection Box)

EGRIFTA SV injection box label for tesamorelin 2 mg/vial, a subcutaneous human prescription drug by Theratechnologies Inc. The label states it is Box 2 of 2 for use with EGRIFTA SV 2 mg/vial and contains sterile injection materials including syringes and needles. Storage instructions specify controlled room temperature 20ºC to 25ºC (68ºF to 77ºF).*

FDA Label Image

Principal Display Panel (2 mg Vial Label)

Label for EGRIFTA SV tesamorelin for injection kit containing 2 mg per vial. Intended for subcutaneous injection only. The label indicates single-dose vial with instructions to discard unused portion. Distributed by Theratechnologies Inc. Directions to store up to 77°F and Rx only status are noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.